as 07-11-2025 3:37pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | CELEBRATION |
Market Cap: | 481.7M | IPO Year: | 2015 |
Target Price: | $23.25 | AVG Volume (30 days): | 1.0M |
Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.86 | EPS Growth: | N/A |
52 Week Low/High: | $5.45 - $12.55 | Next Earning Date: | 08-12-2025 |
Revenue: | $40,588,000 | Revenue Growth: | 46.47% |
Revenue Growth (this year): | 292.31% | Revenue Growth (next year): | 78.65% |
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Insider Monkey
a month ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
Thomson Reuters StreetEvents
2 months ago
GuruFocus.com
2 months ago
Zacks
2 months ago
MT Newswires
2 months ago
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.